Why BofA Downgrades DocuSign Despite Healthy Q1 Print


Although Docusign Inc DOCU reported healthy first-quarter results, its full-year billings guidance was disappointing, reflecting “choppy execution” according to BofA Securities.

The DocuSign Analyst: Brad Sills downgraded the rating for DocuSign from Buy to Neutral, while reducing the price target from $120 to $72.

The DocuSign Thesis: The Buy rating was based on valuation and expectations of improving execution, resulting in sustained mid-teens billings growth in fiscal FY23, Sills said in the downgrade note.

“We are three quarters into the effort to retool the sales organization and the efforts remains a work in progress. Commentary suggests an additional multi quarter effort from here,” the analyst wrote.

“Guidance for FY23 rev growth of 18%, implies mid-teens growth in H2, which is inconsistent with billings guidance, implying mid/high single digit billings growth in H2. This suggests perhaps further downside to already reset FY23 rev estimates,” he added.

DOCU Price Action: Shares of DocuSign had declined by 22.85% to $68.27 at the time of publication Friday.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsTrading IdeasBofA SecuritiesBrad Sills
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!